Transcription of タミフルカプセル75 - database.japic.or.jp
1 1 2019 10 1 87625 10 21200 AMY00238 2001 2 1. 2. 3. 75 1 75mg 75 2 230mg4. A B 5. A B A B 65 A B 6. 1 75mg 1 2 5 1 75mg 1 1 7 10 1 75mg 1 1 10 7.
2 2 48 2 48 mL/ Ccr 301 75mg 1 2 1 75mg 1 1 10 Ccr 301 75mg 1 1 1 75mg Ccr 10 Ccr 8. 2 2 2 9.
3 1 10. 11. X AST ALT -GTP Al-P Stevens-Johnson Toxic Epidermal Necrolysis TEN 1 1 2 1 1 2 2 2 ST ALT -GTP Al-P AST 2 2 2
4 1 2 13. 14. PTP PTP PTP 15. III 1 III 7 100 III / / 65 III 50 23% III 6 12 3 394 657 788 920 1117 1314mg/kg 7 657mg/kg 394mg/kg 7 1314mg/kg 42 / AUC 7 394mg/kg 42 1314mg/kg 16.
5 28 75 150 300mg AUCinf Cmax 1 mg AUCinf ng hr/mL Cmax ng/mL Tmax hr t1/2 hr 1,652 203 150 3,152 702 360 7,235 515 662 ,918 1,5641,377 SD 1 75mg 1 2 5 1 75mg 1 1 7 10 1 75mg 1 1 10 14 75mg1 2 150mg1 2 7 7 AUC0-12h Cmax 3 2 7 mg AUC0-12h ng hr/mL Cmax ng/mL Tmax hr t1/2 hr 75 2,276 527297 2,270 387244 4,891 963599 4,904 477598 SD ng/mL 75mg 75mg 150mg 150mg 3162 116289 107360 14C - 20mg/kg 1 2 1/2 48 3 50% 3% 4 in vitro P450 5 in vitro 300mg 48 70 80% 1 14C - 10mg/kg 1 / 6 80 80 5 75mg 7 80 mg AUCinf
6 Ng hr/mL Cmax ng/mL Tmax hr t1/2 hr 756,063 604439 Ccr 20 100mg1 2 6 8 6 Ccr mL/ AUC0-12h ng hr/mL Cmax ng/mL CLr0-12h L/hr Ccr 3043,086 18,0684,052 1,519 Ccr 6015,010 4,1581,514 392 Ccr 90 9,931 1,6361,058 183 90 4,187 630 494 P450 P450 9 in vitro 4 AUCinf Cmax 2 10 NSAIDs 17. III III JV15823 5 11 2 95% 1 5 122 3 5 130 1 1 75mg 1 2 2 3 p 154 51 10 7 III III WV15670/15671/15730 5 12 2 95% 1 5 301 4 5 309 4 p III III JV15824 42 5 308 19 -83 65 10 18 -77 65 11
7 13 5 1 75mg 1 2 5 1 75mg 1 1 7 10 1 75mg 1 1 10 6 p= 95% 153155 7 13 2 6 1 75mg 1 1 7 2 155 34 8 7 III 18 III WV15673/697 42 5 4 . 8 % 1 . 2 % 14 6 p= 95% 519520 8 25 6 18-64 18-65 8 1 520 250 124 50 32 III WV15825 42 5 15 WV15825n=548 65 9 n=272 n=276 64-96 65-96 9 80% 14% 276 40 5 5 4 III WV15799 7 16 5 WV15799n=955 13 n=461 n=494 12-85 13-82 494 124 27 12
8 9 III WV16193 10 17 WV16193n=808 1 n=392 n=416 1-83 1-80 18. A B IC50 3nM 18 in vitro in vitro A B IC50 155nM IC50 M 19 in vivo A B 100mg/kg/ 20 ,21 24 10 100mg/kg 1 2 22 13 15/2,253 1 12 72/1,698 1 13/71 A B 19.
9 Oseltamivir Phosphate JAN - -Ethyl 3R,4R,5S -4-acetamido-5-amino-3- 1-ethylpropoxy cyclohex-1-ene-1-carboxylate monophosphate C16H28N2O4 H3PO4 95 N,N- 192 195 C 21. 22. 10 PTP10 1 100 PTP10 10 23. 1 JP15734 2000 12 12 .3-1 2 JP15735 2000 12 12 .3-5 3 2000 12 12 .2-2-1 4 2000 12 12 .2-2-4 5 in vitro 2000 12 12 .2-3-2 6 2000 12 12 .2-4-3 7 Abe M, et al. Ann Pharmacother. 2006;40 WP15648 2000 12 12 .3-7-1 9 in vitro 2000 12 12 .2-3-5 10 / WP15728 2000 12 12.
10 3-8-2 11 , .. 2000;74 III WV15670/15671/15730 2000 12 12 .1-3-2 13 , .. 2000;74 III 42 WV15673/15697 2004 7 9 .1-3-2 15 III 42 WV15825 2004 7 9 .1-3-2 16 III 7 WV15799 2004 7 9 .1-3-2 17 III 10 WV16193 2004 7 9 .1-3-2 18 19 A B in vitro 6 20 Sidwell RW, et al. Antiviral Res. 1998;37 Mendel DB, et al. Antimicrob Agents Chemother. 1998;42 24. 103-8324 2-1-1 0120-189706 Fax 0120-189705https A B 26. F. 84014333
